Clinical Trial Update: Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the combination of everolimus and octreotide in patients with advanced carcinoid tumor has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Syndrome
• Carcinoid Tumor

Drugs mentioned

• Afinitor (everolimus)
• OCTREOTIDE (OCTREOTIDE ACETATE)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Carcinoid Tumor, Malignant Carcinoid Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2012-03-12